Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

CPNG

Coupang Inc

May 01 • 04:00PM ET

22.21

Dollar change 0.00
Percentage change 0.00	%

Consumer Cyclical • Internet Retail • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IWP IWF IWR VONG IWB AVEM VT EMQQ PNQI DINT

Index	-	P/E	29.54	EPS (ttm)	0.75	Insider Own	34.58%	Shs Outstand	1.62B	Perf Week	-2.59%
Market Cap	39.83B	Forward P/E	35.74	EPS next Y	0.62	Insider Trans	-11.22%	Shs Float	1.17B	Perf Month	21.83%
Income	1.36B	PEG	-	EPS next Q	0.05	Inst Own	52.74%	Short Float	2.97%	Perf Quarter	58.64%
Sales	24.38B	P/S	1.63	EPS this Y	-61.11%	Inst Trans	0.00%	Short Ratio	2.33	Perf Half Y	29.13%
Book/sh	2.28	P/B	9.73	EPS next Y	113.03%	ROA	11.70%	Short Interest	34.88M	Perf Year	31.26%
Cash/sh	3.12	P/C	7.12	EPS next 5Y	-	ROE	41.81%	52W Range	13.51 - 23.40	Perf YTD	37.18%
Dividend Est.	-	P/FCF	22.94	EPS past 5Y	-	ROI	22.64%	52W High	-5.09%	Beta	1.13
Dividend TTM	-	Quick Ratio	0.90	Sales past 5Y	45.92%	Gross Margin	25.38%	52W Low	64.40%	ATR (14)	0.73
Dividend Ex-Date	-	Current Ratio	1.14	EPS Y/Y TTM	1535.47%	Oper. Margin	1.94%	RSI (14)	64.32	Volatility	3.10% 3.40%
Employees	78000	Debt/Eq	0.68	Sales Y/Y TTM	18.46%	Profit Margin	5.57%	Recom	1.71	Target Price	23.22
Option/Short	Yes / Yes	LT Debt/Eq	0.47	EPS Q/Q	902.11%	Payout	0.00%	Rel Volume	0.00	Prev Close	22.21
Sales Surprise	2.46%	EPS Surprise	850.00%	Sales Q/Q	23.17%	Earnings	May 07 AMC	Avg Volume	14.94M	Price	22.21
SMA20	4.21%	SMA50	14.79%	SMA200	27.69%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-24	Upgrade	Citigroup	Neutral → Buy	$19 → $26
Feb-29-24	Upgrade	Deutsche Bank	Hold → Buy	$18.50 → $21
Jan-16-24	Downgrade	Citigroup	Buy → Neutral	$20 → $17
Dec-20-23	Downgrade	UBS	Buy → Neutral	$26 → $18.50
Aug-09-23	Downgrade	Deutsche Bank	Buy → Hold	$20
Mar-02-23	Downgrade	BofA Securities	Buy → Neutral	$27 → $18
Mar-01-23	Upgrade	Deutsche Bank	Hold → Buy	$20
Feb-09-23	Initiated	Barclays	Overweight	$20
Dec-01-22	Initiated	New Street	Buy	$25
Oct-07-22	Initiated	HSBC Securities	Buy	$27.80
Aug-16-22	Downgrade	CLSA	Outperform → Sell	$16.40
Aug-11-22	Downgrade	Deutsche Bank	Buy → Hold	$15 → $18.50
Aug-09-22	Initiated	Macquarie	Outperform	$26
Jul-01-22	Upgrade	Credit Suisse	Neutral → Outperform	$28 → $19
Jun-29-22	Initiated	Morgan Stanley	Overweight	$18
May-12-22	Upgrade	Citigroup	Neutral → Buy	$29 → $15
May-06-22	Upgrade	JP Morgan	Neutral → Overweight	$25 → $17
Mar-22-22	Upgrade	Deutsche Bank	Hold → Buy
Mar-09-22	Upgrade	UBS	Neutral → Buy
Aug-26-21	Upgrade	Daiwa Securities	Outperform → Buy

Show Previous Ratings

Today 06:15AM	Millionaire-Making Machines: 7 Unstoppable Growth Stocks to Own for the Long Haul (InvestorPlace)
May-01-24 10:00AM	Nearly 50% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 4 Stocks (Motley Fool)
Apr-30-24 10:01AM	Coupang, Inc. (CPNG) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-28-24 09:45AM	My 3 Favorite Stocks to Buy Right Now (Motley Fool)
Apr-26-24 05:45PM	Coupang, Inc. (CPNG) Stock Sinks As Market Gains: Here's Why (Zacks)
02:17AM	Loading…
Apr-24-24 02:17AM	2 Growth Stocks That Could Skyrocket in 2024 (Motley Fool)
Apr-23-24 04:00PM	Coupang to Announce First Quarter 2024 Results on May 7, 2024 (Business Wire)
Apr-21-24 08:45AM	2 Reasons the Smartest Investors Are Watching This Stock, Dubbed the "Amazon of Korea" (Motley Fool)
Apr-18-24 04:33PM	3 Retail Stocks to Buy Now: Q2 Edition (InvestorPlace)
09:09AM	Coupang Stock Has 16% Upside, According to 1 Wall Street Analyst (Motley Fool)
Apr-17-24 01:12PM	Take the Money and Run: 3 Overbought Stocks to Sell ASAP (InvestorPlace)
08:00AM	3 Stocks That Could Turn $1,000 Into $5,000 by 2030 (Motley Fool)
Apr-15-24 01:58PM	Committee stocks on the move: Salesforce, Cisco, Constellation, Coupang, Intel and Rollins (CNBC TV)
10:36AM	Coupang (CPNG) Soars 11.5%: Is Further Upside Left in the Stock? (Zacks)
Apr-12-24 08:39PM	Coupang Stock (NYSE:CPNG): Should You Ride This Rocket Higher? (TipRanks) +11.49%
04:35PM	Loading…
04:35PM	Coupang, IBD Stock Of The Day, Breaks Out After Membership Price Increase (Investor's Business Daily)
02:05PM	Why Coupang (CPNG) Stock Is Trading Up Today (StockStory)
01:35PM	Why Coupang Stock Was Climbing Today (Motley Fool)
12:02PM	Higher Membership Fees Supercharge Coupang (CPNG) Stock (InvestorPlace)
Apr-11-24 10:00AM	4 Reasons to Buy Coupang Stock Like There's No Tomorrow (Motley Fool)
Apr-03-24 06:00AM	3 E-commerce Stocks to Buy for Multibagger Returns in 3 Years (InvestorPlace)
Apr-02-24 04:00PM	3 Global Stocks That Can Double in the Second Half of 2024 (InvestorPlace)
Apr-01-24 07:21AM	A Look Back at Online Marketplace Stocks' Q4 Earnings: Coupang (NYSE:CPNG) Vs The Rest Of The Pack (StockStory)
Mar-31-24 04:25AM	A Bull Market Is Here: 2 Tech Stocks Down 44% and 65% to Buy Right Now (Motley Fool)
Mar-29-24 09:45AM	2 Things the Smart Investors Know About Coupang, the "Amazon of Korea" (Motley Fool)
Mar-28-24 10:30AM	Got $1,000? 2 Stocks to Buy Now While They're On Sale (Motley Fool)
Mar-22-24 03:25PM	Corporate Insiders are Dumping These 11 Tech Stocks (Insider Monkey)
Mar-19-24 09:13AM	Goldman Sachs Says Buy AI Beneficiaries Beyond the High Momentum Stocks; Here Are 3 Names to Consider (TipRanks)
Mar-16-24 06:00AM	Billionaire Investor Stanley Druckenmiller Has 40% of His Portfolio in 3 AI Stocks. Are any of Them Buys? (Motley Fool)
Mar-15-24 11:04AM	Hypergrowth Hitlist: 7 Stocks Primed to Skyrocket 100% in the Next 9 Months (InvestorPlace)
06:00PM	Loading…
Mar-11-24 06:00PM	Stanley Druckenmiller's Secret Sauce: The Two Stocks Dominating a Quarter of His Three Billion Dollar Portfolio (Benzinga)
Mar-08-24 09:40AM	Why Coupang Soared 32.3% in February (Motley Fool)
Mar-07-24 02:59AM	Got $20? Buy This Korean E-commerce Stock Before It's Too Late (Motley Fool)
Mar-06-24 01:01PM	Baillie Gifford Bolsters Stake in Coupang Inc (GuruFocus.com)
06:54AM	Asias E-Commerce Battlefield Is Expanding Fast (The Wall Street Journal)
Mar-05-24 12:10PM	Goodbye, Project Titan (Motley Fool)
09:20AM	30 Cities with Most Illegal Immigrants in the US (Insider Monkey)
08:00AM	Coupang Partners with the U.S. Department of Commerce to Co-host EMPOWER Asia Webinars to Promote U.S. Exports (Business Wire)
Mar-03-24 08:52AM	The Ultimate Growth Stock to Buy With $1,000 Right Now (Motley Fool)
Mar-01-24 12:25PM	Why Coupang Stock Jumped This Week (Motley Fool)
Feb-29-24 09:01AM	Coupang, Inc. (NYSE:CPNG) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:07AM	Decoding Coupang Inc (CPNG): A Strategic SWOT Insight (GuruFocus.com)
Feb-28-24 01:50PM	Top 20 E-Commerce Companies in the World (Insider Monkey) +7.99%
12:13PM	Why Coupang (CPNG) Stock Is Up Today (StockStory)
11:32AM	Best Stock to Buy Now: Is Coupang Stock a Buy After Earnings? (Motley Fool)
10:35AM	José Neves Takes Control of Namesake Foundation Based in Portugal (WWD)
10:15AM	Stocks to Watch Wednesday: Coinbase, Beyond Meat, AMC (The Wall Street Journal)
10:12AM	Why Is Coupang (CPNG) Stock Up 4% Today? (InvestorPlace)
09:20AM	Q4 2023 Coupang Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 09:00PM	Coupang (CPNG) Q4 2023 Earnings Call Transcript (Motley Fool)
07:09PM	Coupang Soars After Loyalty Perks Lift Sales Above Estimates (Bloomberg)
06:48PM	Farfetch Still Dreams of Luxury Dominance Under New Owner Coupang (WWD)
04:42PM	Coupang Inc (CPNG) Reports Strong Q4 and Full-Year 2023 Financial Results (GuruFocus.com)
04:09PM	Coupang's (NYSE:CPNG) Q4: Beats On Revenue, Stock Soars (StockStory)
04:00PM	Coupang Announces Results for Fourth Quarter 2023 (Business Wire)
Feb-26-24 10:15AM	Coupang: Buy, Sell, or Hold? (Motley Fool)
02:01AM	Coupang Earnings: What To Look For From CPNG (StockStory)
Feb-23-24 01:35AM	Should You Invest in Coupang (CPNG)? (Insider Monkey)
Feb-22-24 09:53AM	Got $1,000? Buy These Hot Growth Stocks Before They Take Off (Motley Fool)
08:45AM	1 Growth Stock Down 70% You'll Wish You'd Bought at Today's Near-All-Time-Low Valuation (Motley Fool)
Feb-19-24 08:57AM	Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now. (Motley Fool)
Feb-16-24 03:15AM	20 Fastest Growing E-Commerce Companies in 2024 (Insider Monkey)
Feb-15-24 05:04PM	7 Undervalued Growth Stocks to Buy for 10x Returns by 2030 (InvestorPlace)
01:47PM	Hedge Fund and Insider Trading News: Daniel Loeb, Michael Burry, Cathie Wood, Bridgewater Associates, Tiger Management, Maverick Capital, Soros Fund Management, AutoNation, Inc. (AN), and More (Insider Monkey)
10:15AM	José Neves Steps Down as Farfetch CEO in Shakeup at Coupang (WWD)
Feb-14-24 12:01PM	Tiger Management's Bet on Coupang Inc. Dominates Q4 Portfolio with a 26.69% Stake (GuruFocus.com)
Feb-13-24 04:00PM	Coupang to Announce Fourth Quarter 2023 Results on February 27, 2024 (Business Wire)
01:40PM	The Next Amazon? 3 E-Commerce Stocks That Investors Shouldnt Ignore. (InvestorPlace)
Feb-10-24 02:06AM	20 Best Countries to Relocate to (Insider Monkey)
Feb-08-24 11:54AM	Kering Pulls Brands Off Farfetch in Wake of Sale to Coupang (WWD)
07:02AM	Bergdorf Goodman to run its own e-commerce as parent Neiman Marcus Group drops Farfetch (Retail Dive)
Feb-07-24 02:15PM	Neiman Marcus Group Severs Commercial Ties to Farfetch (WWD)
Feb-06-24 05:30AM	2 No-Brainer Growth Stocks to Buy Now With $20 and Hold Long-Term (Motley Fool)
Feb-04-24 11:56AM	Farfetch founder destroyed its value to rush through takeover, filings claim (The Telegraph)
Feb-01-24 04:57AM	Billionaire Stanley Druckenmiller Has 39% of His Portfolio Invested in 3 Brilliant Growth Stocks (Motley Fool)
01:59AM	Billionaire Investor Stan Druckenmiller Has 38% of His Portfolio in 3 Growth Stocks: 1 of Them May Surprise You (Motley Fool)
Jan-31-24 11:02PM	Baillie Gifford Bolsters Stake in Coupang Inc (GuruFocus.com)
01:13PM	Farfetch Bondholders Are Pushing Back on Sale of Luxury-Goods Company (Barrons.com)
10:55AM	Coupang Finalizes Purchase of Troubled Farfetch (Sourcing Journal)
04:00AM	Coupang Completes Acquisition of Farfetch (Business Wire)
Jan-29-24 01:20PM	3 Outperforming Emerging Market Stocks for Your Watch List (InvestorPlace)
01:00AM	Farfetch Wants to Wipe Out Some Bondholders. Theyre Fighting Back. (Barrons.com)
Jan-27-24 07:58AM	3 Top Growth Stocks to Buy Hand Over Fist in February (Motley Fool)
05:15AM	The Best Stocks to Buy With $2,000 Right Now (Motley Fool)
Jan-26-24 02:55PM	Bond Holders Challenge Coupangs Rescue of Troubled Farfetch (WWD)
Jan-22-24 09:28AM	15 Best Affordable Stocks To Buy Now (Insider Monkey)
Jan-19-24 06:22PM	Why Coupang Stock Stumbled to an 11% Loss This Week (Motley Fool)
Jan-15-24 09:23AM	1 Growth Stock Down 67% to Buy Hand Over Fist in 2024 (Motley Fool)
Jan-14-24 08:15AM	1 Growth Stock Down 68% to Buy Right Now (Motley Fool)
Jan-13-24 06:10AM	3 Growth Stocks to Buy and Hold Forever (Motley Fool)
Jan-10-24 04:38PM	Why Googles AI Thinks These 3 Stocks Can Double in 2024 (InvestorPlace)
Jan-08-24 10:15AM	Got $1,000? 3 Stocks to Buy Now While They're on Sale (Motley Fool)
Jan-07-24 03:34PM	3 Compelling Asian Retail Stocks to Diversify Your Portfolio in 2024 (InvestorPlace)
03:24PM	The 3 Hottest E-Commerce Stocks to Watch in 2024 (InvestorPlace)
Jan-02-24 10:37PM	Down 77% from Highs, Can Coupang Stock (NYSE:CPNG) Recover in 2024? (TipRanks)
12:01PM	3 Emerging Market Stocks That Can Double in 2024 (InvestorPlace)
11:15AM	2 Growth Stocks Down 67% and 88% to Buy at the Start of 2024 (Motley Fool)
Dec-31-23 09:18AM	Investing for Retirement; Finding a Mint Replacement; Closing Credit Cards (Motley Fool)
Dec-28-23 04:51PM	Growth Galore: 7 Long-Term Stock Picks for Prolonged Prosperity (InvestorPlace)
Dec-24-23 02:20PM	7 Top Growth Stocks to Buy BEFORE They Take Off in 2024 (InvestorPlace)

Coupang, Inc. engages in operating an e-commerce platform. It operates through the following segments: Product Commerce and Developing Offerings segments. The Product Commerce segment provides core retail and marketplace offerings and Rocket Fresh, as well as advertising products associated with these offerings. The Developing Offerings segment includes nascent offerings and services, including Coupang Eats, Coupang Play, international and fintech initiatives. The company was founded in 2010 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rogers Harold	See Remarks	Mar 18 '24	Sale	18.25	139,080	2,538,210	394,192	Mar 19 05:21 PM
MEHTA NEIL	Director	Mar 14 '24	Sale	18.68	1,600,000	29,894,831	48,006,135	Mar 18 09:32 PM
SVF Investments (UK) Ltd	10% Owner	Mar 13 '24	Sale	19.60	15,000,000	294,000,000	349,542,259	Mar 14 09:00 PM
SVF Investments (UK) Ltd	10% Owner	Mar 12 '24	Sale	19.01	31,614,154	600,927,187	364,542,259	Mar 14 09:00 PM
Kang Hanseung	Rep Director, Business Mngmt	Mar 12 '24	Sale	19.25	48,000	924,000	519,987	Mar 13 04:48 PM
Kolari Pranam	See Remarks	Feb 02 '24	Sale	13.88	2,356	32,701	182,844	Feb 06 06:09 PM
Kim Tae Jung	See Remarks	Jan 02 '24	Sale	16.00	5,350	85,600	248,240	Jan 03 05:56 PM
Kim Tae Jung	See Remarks	Dec 04 '23	Sale	15.50	940	14,570	253,590	Dec 05 06:52 PM
SVF Investments (UK) Ltd	10% Owner	Nov 29 '23	Sale	15.39	30,000,000	461,700,000	396,156,413	Dec 01 09:00 PM
Kim Tae Jung	See Remarks	Oct 02 '23	Sale	16.95	4,673	79,207	254,530	Oct 03 07:02 PM
Kim Tae Jung	See Remarks	Sep 05 '23	Sale	18.99	939	17,832	259,203	Sep 06 05:17 PM
Kim Tae Jung	See Remarks	Jul 03 '23	Sale	17.56	4,671	82,023	260,142	Jul 05 06:01 PM
Sun Benjamin	Director	Jun 12 '23	Sale	16.04	150,000	2,406,000	303,312	Jun 14 07:40 PM
Kim Tae Jung	See Remarks	Jun 02 '23	Sale	16.47	940	15,482	264,813	Jun 05 06:52 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	May 24 '23	Sale	15.37	1,000,000	15,370,000	67,651,928	May 25 08:01 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	May 23 '23	Sale	15.61	2,000,000	31,220,000	68,651,928	May 25 08:01 PM
Franceschi Pedro	Director	May 19 '23	Sale	15.99	7,143	114,217	21,428	May 22 06:03 PM
Kang Hanseung	Rep Director, Business Mngmt	May 15 '23	Sale	16.00	174,324	2,789,184	475,743	May 16 06:15 AM

Open in Screener

ROIV

Roivant Sciences Ltd

May 01 • 04:00PM ET

11.21

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ROIV Roivant Sciences Ltd daily Stock Chart

Held by: IJH VXF IBB FXH IWP IJK IWF IWR VHT SCHM

Index	-	P/E	2.15	EPS (ttm)	5.21	Insider Own	31.57%	Shs Outstand	760.14M	Perf Week	2.84%
Market Cap	9.03B	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-1.20%	Shs Float	551.48M	Perf Month	2.66%
Income	4.47B	PEG	-	EPS next Q	-0.28	Inst Own	51.37%	Short Float	8.18%	Perf Quarter	12.10%
Sales	123.24M	P/S	73.30	EPS this Y	550.87%	Inst Trans	2.60%	Short Ratio	6.45	Perf Half Y	32.66%
Book/sh	7.57	P/B	1.48	EPS next Y	-122.64%	ROA	91.47%	Short Interest	45.13M	Perf Year	30.05%
Cash/sh	8.28	P/C	1.35	EPS next 5Y	-	ROE	123.54%	52W Range	8.06 - 13.24	Perf YTD	-0.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.79%	ROI	68.29%	52W High	-15.33%	Beta	1.29
Dividend TTM	-	Quick Ratio	27.77	Sales past 5Y	571.16%	Gross Margin	72.86%	52W Low	39.08%	ATR (14)	0.36
Dividend Ex-Date	-	Current Ratio	27.79	EPS Y/Y TTM	411.84%	Oper. Margin	-850.46%	RSI (14)	56.79	Volatility	2.99% 3.25%
Employees	904	Debt/Eq	0.08	Sales Y/Y TTM	185.76%	Profit Margin	3624.14%	Recom	1.17	Target Price	16.08
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	1322.86%	Payout	-	Rel Volume	0.00	Prev Close	11.21
Sales Surprise	16.89%	EPS Surprise	2051.46%	Sales Q/Q	117.80%	Earnings	Feb 13 BMO	Avg Volume	7.00M	Price	11.21
SMA20	1.91%	SMA50	2.73%	SMA200	5.44%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

May-01-24 10:47AM	3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 (InvestorPlace)
Apr-25-24 08:00AM	Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis (Business Wire)
Apr-12-24 11:09AM	10 Most Undervalued Stocks to Buy for Under $20 (Insider Monkey)
Apr-02-24 07:00AM	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million (GlobeNewswire)
Mar-27-24 01:55PM	Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck (The Wall Street Journal) +7.54%
06:22PM	Loading…
Mar-26-24 06:22PM	Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 (PR Newswire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Feb-15-24 02:45AM	Do You Think the Management of Roivant Sciences (ROIV) Can Create Value? (Insider Monkey)
Feb-13-24 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update (GlobeNewswire)
Feb-10-24 02:55AM	Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares (GuruFocus.com)
Jan-30-24 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 (GlobeNewswire)
Dec-27-23 08:05PM	5 High Growth International Stocks to Buy (Insider Monkey)
Dec-20-23 04:30PM	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire) -7.78%
Dec-14-23 09:00AM	Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease (GlobeNewswire)
07:00AM	Loading…
Nov-28-23 07:00AM	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire)
02:38AM	5 Stocks Under $20 To Buy Now (Insider Monkey)
Nov-27-23 08:00AM	Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus (GlobeNewswire)
Nov-14-23 01:00PM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update (GlobeNewswire)
Nov-10-23 08:00AM	Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors (GlobeNewswire)
Oct-30-23 05:30PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 (GlobeNewswire)
Oct-24-23 08:00AM	This $5 Billion Biotech Home Run Took Less Than a Year (The Wall Street Journal)
Oct-23-23 03:02PM	Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion (Investopedia) -11.02%
10:31AM	Why Is Roivant Sciences (ROIV) Stock Up Today? (InvestorPlace)
09:52AM	Roche acquires Telavant, rights to bowel disease drug (Yahoo Finance Video)
06:55AM	Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion (The Wall Street Journal)
03:49AM	Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln Deal (The Wall Street Journal)
01:00AM	Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant (GlobeNewswire)
Oct-13-23 08:00AM	Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer (GlobeNewswire)
05:01AM	Loading…
Oct-05-23 05:01AM	Insider Sell: Eric Venker Sells 1,200,000 Shares of Roivant Sciences Ltd (ROIV) (GuruFocus.com) +5.04%
Oct-03-23 07:00AM	Vivek Ramaswamys Former Company Is Doing Just Fine Without Him (The Wall Street Journal)
Sep-30-23 05:00AM	Insider Sell: President & COO Eric Venker Sells 500,000 Shares of Roivant Sciences Ltd (ROIV) (GuruFocus.com)
Sep-26-23 06:00AM	Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results (GlobeNewswire) +21.55%
Sep-11-23 08:00AM	Roivant Announces Completion of Redemption of its Outstanding Warrants (GlobeNewswire) -8.65%
Sep-09-23 10:51AM	The Brash Strategy That Made Vivek Ramaswamy a Fortune (The Wall Street Journal)
Aug-17-23 04:05PM	Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants (GlobeNewswire)
Aug-14-23 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update (GlobeNewswire)
Aug-03-23 04:05PM	Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023 (GlobeNewswire)
Aug-02-23 04:05PM	Roivant Announces Redemption of Outstanding Warrants (GlobeNewswire)
Jul-27-23 08:00AM	Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohns Disease (GlobeNewswire)
Jul-26-23 10:21AM	Big Short Steve Eisman Says the Stock Market Will Continue Surging as No Recession Signs Emerge Here Are 2 Stocks That Analysts Like (TipRanks)
Jul-13-23 05:50PM	Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion (The Wall Street Journal)
Jul-11-23 08:00AM	Roivant Ranks No. 25 on Fast Companys Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program (GlobeNewswire)
Jun-28-23 08:57AM	UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update (GlobeNewswire) +11.27%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update (GlobeNewswire)
Jun-26-23 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023 (GlobeNewswire) -6.33%
Jun-22-23 07:30AM	Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period (GlobeNewswire)
Jun-21-23 05:00PM	Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis (GlobeNewswire)
May-16-23 07:00AM	Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old (GlobeNewswire)
Apr-04-23 07:37AM	Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory (Business Wire)
07:37AM	Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research (Business Wire)
Mar-28-23 08:00AM	Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients (GlobeNewswire)
Mar-15-23 07:45AM	Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old (GlobeNewswire) +7.91%
Mar-14-23 04:07PM	Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis (GlobeNewswire)
08:00AM	Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs (GlobeNewswire)
Mar-07-23 08:00AM	Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement (GlobeNewswire)
Feb-21-23 08:32PM	Roivant Sciences Announces Change to its Board of Directors (GlobeNewswire)
Feb-13-23 04:17PM	Collecting Pharmas Scraps Can Pay Off for This Biotech (The Wall Street Journal)
07:00AM	Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update (GlobeNewswire)
Feb-02-23 09:14PM	Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares (GlobeNewswire) -11.12%
Feb-01-23 04:05PM	Roivant Sciences Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Jan-30-23 08:00AM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023 (GlobeNewswire)
Jan-04-23 06:05AM	Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient Populations (GlobeNewswire) +5.73%
Dec-07-22 06:30AM	Edison Partners leads $21 million funding round for clinical trial intelligence disruptor Lokavant (PR Newswire)
Dec-01-22 08:00AM	Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases (GlobeNewswire) +8.21%
Nov-14-22 07:00AM	Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update (GlobeNewswire)
Nov-10-22 09:00AM	Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC (GlobeNewswire)
Nov-08-22 06:15AM	Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering (GlobeNewswire) -11.19%
Nov-07-22 04:01PM	Roivant Sciences Announces Proposed Public Equity Offering (GlobeNewswire)
Oct-18-22 04:00PM	Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences (GlobeNewswire)
Aug-30-22 07:00AM	Roivant to Participate in September Investor Events (GlobeNewswire)
Aug-16-22 11:44AM	Time To Worry? Analysts Are Downgrading Their Roivant Sciences Ltd. (NASDAQ:ROIV) Outlook (Simply Wall St.)
Aug-15-22 07:00AM	Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update (GlobeNewswire)
Aug-14-22 10:53AM	Investors in Roivant Sciences (NASDAQ:ROIV) from a year ago are still down 56%, even after 16% gain this past week (Simply Wall St.)
Aug-03-22 07:00AM	Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022 (GlobeNewswire)
Jul-23-22 09:00AM	Roivant Sciences Ltd.'s (NASDAQ:ROIV) Intrinsic Value Is Potentially 34% Above Its Share Price (Simply Wall St.)
Jun-30-22 09:18AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.) -9.35%
Jun-28-22 06:27AM	Roivant, Pfizer unveil Priovant Therapeutics focused on autoimmune disease treatments, Roivant stock surges (MarketWatch)
06:10AM	Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update (GlobeNewswire)
06:00AM	Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus (GlobeNewswire)
Jun-15-22 04:30PM	Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022 (GlobeNewswire) +7.90%
May-24-22 06:00AM	FDA Approves Dermavants VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years (GlobeNewswire) +7.12%
May-19-22 04:30PM	Roivant to Present at Upcoming Investor Conferences (GlobeNewswire)
May-16-22 07:00AM	Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
May-09-22 11:16AM	What Type Of Shareholders Own The Most Number of Roivant Sciences Ltd. (NASDAQ:ROIV) Shares? (Simply Wall St.) -12.71%
May-02-22 07:00AM	Roivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation (GlobeNewswire)
Apr-20-22 07:00AM	VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders (GlobeNewswire)
Apr-13-22 07:00AM	VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen (GlobeNewswire)
Mar-25-22 08:01AM	Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting (GlobeNewswire)
Mar-24-22 07:00AM	Sanford Burnham Prebys and Roivant Social Ventures Announce Groundbreaking Partnership to Increase Diversity & Inclusion in Biopharma (GlobeNewswire)
Mar-11-22 04:45PM	Roivant to Present at Targeted Protein Degradation Conference (GlobeNewswire)
Mar-07-22 11:18AM	Roivant Sciences (NASDAQ:ROIV) dips 14% this week as increasing losses might not be inspiring confidence among its investors (Simply Wall St.)
Feb-28-22 06:01AM	Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna (GlobeNewswire)
Feb-14-22 07:00AM	Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update (GlobeNewswire) +5.11%
Feb-07-22 07:00AM	Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022 (GlobeNewswire)
Jan-25-22 04:30PM	Roivant to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-05-22 04:30PM	Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.52%
10:39AM	Goldman Sachs Predicts Over 60% Rally for These 3 Stocks (TipRanks)
Dec-16-21 10:00AM	Virtual Reality Startup Nanome Announces Largest Deployment to Date (GlobeNewswire)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venker Eric	President & COO	Feb 09 '24	Option Exercise	3.85	96,950	373,258	629,157	Feb 09 09:00 PM
Venker Eric	President & COO	Feb 09 '24	Sale	10.92	96,950	1,058,694	532,207	Feb 09 09:00 PM
Ramaswamy Vivek	10% Owner	Jan 02 '24	Sale	11.05	3,000,000	33,150,000	51,929,426	Jan 03 04:56 PM
Venker Eric	Chief Operating Officer	Oct 05 '23	Sale	10.11	153,027	1,547,103	595,397	Oct 04 09:30 PM
Venker Eric	Chief Operating Officer	Oct 04 '23	Option Exercise	3.85	153,027	589,154	748,424	Oct 04 09:30 PM
Venker Eric	Chief Operating Officer	Oct 03 '23	Option Exercise	3.85	606,221	2,333,951	1,201,618	Oct 04 09:30 PM
Venker Eric	Chief Operating Officer	Oct 03 '23	Sale	10.25	606,221	6,213,765	595,397	Oct 04 09:30 PM
Venker Eric	Chief Operating Officer	Oct 02 '23	Option Exercise	3.85	440,752	1,696,895	1,036,149	Oct 04 09:30 PM
Roivant Sciences Ltd.	Director	Oct 02 '23	Buy	38.00	1,526,316	58,000,008	79,805,331	Oct 04 05:15 PM
Venker Eric	Chief Operating Officer	Oct 02 '23	Sale	10.80	440,752	4,760,122	595,397	Oct 04 09:30 PM
SVF Investments (UK) Ltd	10% Owner	Sep 28 '23	Sale	12.60	10,000,000	126,000,000	73,031,667	Oct 02 09:00 PM
QVT Financial LP	Director by Deputization	Sep 28 '23	Sale	11.55	10,000,000	115,500,000	100,804	Oct 02 08:43 PM
Gold Daniel Allen	Director	Sep 28 '23	Sale	11.55	10,000,000	115,500,000	100,804	Oct 02 08:55 PM
MANCHESTER KEITH S	Director	Sep 28 '23	Sale	11.55	6,896,144	79,650,463	5,023,787	Oct 02 09:05 PM
Venker Eric	President & COO	Sep 27 '23	Option Exercise	3.85	500,000	1,925,000	1,095,397	Sep 29 09:30 PM
Venker Eric	President & COO	Sep 27 '23	Sale	13.02	500,000	6,510,000	595,397	Sep 29 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Sep 08 '23	Option Exercise	6.48	99,350	643,788	297,300	Sep 12 09:30 PM
Venker Eric	Chief Operating Officer	Sep 08 '23	Option Exercise	3.85	106,430	409,756	718,243	Sep 12 09:32 PM
Venker Eric	Chief Operating Officer	Sep 08 '23	Sale	12.19	106,430	1,297,382	611,813	Sep 12 09:32 PM
Kumar Rakhi	Chief Accounting Officer	Sep 08 '23	Sale	12.18	99,350	1,210,083	197,950	Sep 12 09:30 PM
Venker Eric	Chief Operating Officer	Sep 06 '23	Option Exercise	3.85	5,926	22,815	617,739	Sep 06 09:30 PM
Venker Eric	Chief Operating Officer	Sep 06 '23	Sale	11.85	5,926	70,223	611,813	Sep 06 09:30 PM
Venker Eric	Chief Operating Officer	Sep 05 '23	Option Exercise	3.85	73,275	282,109	685,088	Sep 06 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Sep 05 '23	Option Exercise	6.48	1,724	11,172	199,674	Sep 07 09:30 PM
Venker Eric	Chief Operating Officer	Sep 05 '23	Sale	11.92	73,275	873,438	611,813	Sep 06 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Sep 05 '23	Sale	12.00	1,724	20,688	197,950	Sep 07 09:30 PM
Venker Eric	Chief Operating Officer	Sep 01 '23	Option Exercise	3.85	14,763	56,838	626,576	Sep 06 09:30 PM
Venker Eric	Chief Operating Officer	Sep 01 '23	Sale	11.90	14,763	175,680	611,813	Sep 06 09:30 PM
Venker Eric	Chief Operating Officer	Aug 14 '23	Option Exercise	3.85	59,811	230,272	687,729	Aug 16 09:34 PM
Venker Eric	Chief Operating Officer	Aug 14 '23	Sale	11.89	59,811	711,153	627,918	Aug 16 09:34 PM
Venker Eric	Chief Operating Officer	Aug 03 '23	Option Exercise	3.85	44,629	171,822	672,547	Aug 07 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Aug 03 '23	Option Exercise	6.48	3,681	23,853	203,009	Aug 03 09:30 PM
Venker Eric	Chief Operating Officer	Aug 03 '23	Sale	11.93	44,629	532,424	627,918	Aug 07 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Aug 03 '23	Sale	12.00	3,681	44,172	199,328	Aug 03 09:30 PM
Venker Eric	Chief Operating Officer	Aug 02 '23	Option Exercise	3.85	16,397	63,128	644,315	Aug 02 09:30 PM
Venker Eric	Chief Operating Officer	Aug 02 '23	Sale	11.86	16,397	194,468	627,918	Aug 02 09:30 PM
Venker Eric	Chief Operating Officer	Aug 01 '23	Option Exercise	3.85	61,397	236,378	689,315	Aug 02 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Aug 01 '23	Option Exercise	6.48	336	2,177	199,664	Aug 03 09:30 PM
Venker Eric	Chief Operating Officer	Aug 01 '23	Sale	11.92	61,397	731,852	627,918	Aug 02 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Aug 01 '23	Sale	12.00	336	4,032	199,328	Aug 03 09:30 PM
Venker Eric	Chief Operating Officer	Jul 31 '23	Option Exercise	3.85	117,372	451,882	745,290	Aug 02 09:30 PM
Venker Eric	Chief Operating Officer	Jul 31 '23	Sale	11.91	117,372	1,397,901	627,918	Aug 02 09:30 PM
Venker Eric	Chief Operating Officer	Jul 27 '23	Option Exercise	3.85	23,622	90,945	651,540	Jul 27 09:30 PM
Venker Eric	Chief Operating Officer	Jul 27 '23	Sale	10.98	23,622	259,370	627,918	Jul 27 09:30 PM
Venker Eric	Chief Operating Officer	Jul 26 '23	Option Exercise	3.85	73,568	283,237	701,486	Jul 27 09:30 PM
Venker Eric	Chief Operating Officer	Jul 26 '23	Sale	10.91	73,568	802,627	627,918	Jul 27 09:30 PM
Venker Eric	Chief Operating Officer	Jul 25 '23	Option Exercise	3.85	28,344	109,124	656,262	Jul 27 09:30 PM
Venker Eric	Chief Operating Officer	Jul 25 '23	Sale	10.86	28,344	307,816	627,918	Jul 27 09:30 PM
Venker Eric	President & COO	Jul 24 '23	Option Exercise	3.85	33,081	127,362	677,296	Jul 24 09:31 PM
Venker Eric	President & COO	Jul 24 '23	Sale	10.93	33,081	361,575	644,215	Jul 24 09:31 PM
Venker Eric	President & COO	Jul 21 '23	Option Exercise	3.85	181,998	700,692	826,213	Jul 24 09:31 PM
Venker Eric	President & COO	Jul 21 '23	Sale	11.13	181,998	2,025,638	644,215	Jul 24 09:31 PM
Venker Eric	President & COO	Jul 20 '23	Option Exercise	3.85	159,387	613,640	803,602	Jul 24 09:31 PM
Venker Eric	President & COO	Jul 20 '23	Sale	11.31	159,387	1,802,667	644,215	Jul 24 09:31 PM
Kumar Rakhi	Chief Accounting Officer	Jul 18 '23	Option Exercise	6.48	100	648	82,228	Jul 18 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Jul 18 '23	Sale	12.00	100	1,200	82,128	Jul 18 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Jul 14 '23	Option Exercise	6.48	535	3,467	82,663	Jul 18 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Jul 14 '23	Sale	12.00	535	6,420	82,128	Jul 18 09:30 PM
Sumitomo Chemical Co., Ltd.	10% Owner	Jun 22 '23	Sale	8.60	15,116,277	129,999,982	71,251,083	Jun 26 04:05 PM
VIKING GLOBAL PERFORMANCE LLC	10% Owner	Jun 22 '23	Sale	9.90	13,000,000	128,700,000	641,010	Jun 26 05:10 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jun 22 '23	Sale	9.90	13,000,000	128,700,000	641,010	Jun 26 05:11 PM
Venker Eric	President & COO	Jun 09 '23	Option Exercise	3.85	299,384	1,152,628	959,481	Jun 09 09:32 PM
Kumar Rakhi	Chief Accounting Officer	Jun 09 '23	Option Exercise	5.12	43,893	224,732	242,475	Jun 13 09:31 PM
Venker Eric	President & COO	Jun 09 '23	Sale	9.91	299,384	2,966,895	660,097	Jun 09 09:32 PM
Kumar Rakhi	Chief Accounting Officer	Jun 09 '23	Sale	9.93	43,893	435,857	198,582	Jun 13 09:31 PM
Venker Eric	President & COO	Jun 07 '23	Option Exercise	3.85	201	774	660,298	Jun 09 09:32 PM
Venker Eric	President & COO	Jun 07 '23	Sale	9.85	201	1,980	660,097	Jun 09 09:32 PM
Venker Eric	President & COO	May 23 '23	Option Exercise	3.85	415	1,598	676,183	May 25 09:30 PM
Venker Eric	President & COO	May 23 '23	Sale	9.85	415	4,088	675,768	May 25 09:30 PM
Venker Eric	President & COO	May 09 '23	Option Exercise	3.85	238,724	919,087	914,492	May 11 09:33 PM
Venker Eric	President & COO	May 09 '23	Sale	9.23	238,724	2,203,423	675,768	May 11 09:33 PM
Venker Eric	President & COO	May 08 '23	Option Exercise	3.85	61,206	235,643	736,974	May 08 09:30 PM
Venker Eric	President & COO	May 08 '23	Sale	8.93	61,206	546,570	675,768	May 08 09:30 PM
Venker Eric	President & COO	May 04 '23	Option Exercise	3.85	88,838	342,026	764,606	May 08 09:30 PM
Venker Eric	President & COO	May 04 '23	Sale	8.30	88,838	737,355	675,768	May 08 09:30 PM
Venker Eric	President & COO	May 03 '23	Option Exercise	3.85	118,760	457,226	794,528	May 03 09:30 PM
Venker Eric	President & COO	May 03 '23	Sale	8.40	118,760	997,584	675,768	May 03 09:30 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

CPNG

Coupang Inc

ROIV

Roivant Sciences Ltd

Upgrade your FINVIZ experience